Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2026 (Specifically September 9, 2026)
Context: This filing incorporates by reference a press release regarding clinical data publication for the company's drug candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves solely to disseminate a specific press release and does not contain financial statements or a financial summary.
Material Changes
Clinical Development Update: The company announced the publication of a report detailing improvements in decompensated cirrhosis patients treated with Namodenoson. The report also highlights successful bridging to liver transplantation for these patients.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses exclusively on the positive clinical outcomes reported in the attached press release (Exhibit 99.1).
Guidance and Risks: The filing text does not provide updated financial guidance, specific risk factors, or contingencies beyond the general context of clinical development.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the specific clinical trial data and patient population size.
- Confirm the journal or conference where the Namodenoson results were published.
- Review the company's most recent Form 20-F or quarterly reports for current cash runway and burn rate, as this filing contains no financial data.
- Assess the regulatory implications of "successful bridging to liver transplantation" for future FDA or EMA approval pathways.